Results 21 to 30 of about 2,383,672 (201)
The t(11;14) (q13;q32) translocation resulting in overexpression of cyclin D1 is the major oncogenic mechanism in mantle cell lymphoma (MCL). Most MCLs can be diagnosed based on morphological features, cyclin D1 expression, and IGH/CCND1 rearrangement ...
Luomengjia Dai +21 more
doaj +1 more source
Multi-Compartment and Multi-Host Vector Suite for Recombinant Protein Expression and Purification
Recombinant protein expression has become an invaluable tool in basic and applied research. The accumulated knowledge in this field allowed the expression of thousands of protein targets in a soluble, pure, and homogeneous state, essential for ...
Claudia Ortega +9 more
doaj +1 more source
The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives
Hairy cell leukemia (HCL) is an incurable, rare lymphoproliferative hematological malignancy of mature B cAlthough first line therapy with purine analogues leads to positive results, almost half of HCL patients relapse after 5-10 years, and standard ...
Ernesto Gargiulo +9 more
doaj +1 more source
Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6 [PDF]
The authors acknowledge TENOVUS Tayside for funding the studyTenovin-6 (Tnv-6) is a bioactive small molecule with anti-neoplastic activity. Inhibition of the Sirtuin class of protein deacetylases with activation of p53 function is associated with the pro-
Coates, Philip J. +44 more
core +1 more source
Background: Leukemia is a group of cancers that usually begin in the bone marrow and results in a large number of abnormal white blood cells. Chronic Lymphocytic Leukemia is the most prevalent leukemia in Western countries, with an estimated incidence ...
Gedam Derbew Addisia +9 more
doaj +1 more source
Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism. Due to its catalytic activity, LPL is involved in metabolic pathways exploited by various solid and hematologic malignancies to provide an extra energy source to the tumor cell.
Daniel Prieto, Pablo Oppezzo
doaj +1 more source
Chronic lymphocytic leukemia therapy guided by measurable residual disease
Background: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy.
Pettitt, Andrew +31 more
core +1 more source
Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients [PDF]
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM, Salma Al Dallal
core +1 more source
Disease-specific complications of chronic lymphocytic leukemia in binet stage a patients [PDF]
Disease-specific Complications of Chronic Lymphocytic Leukemia in Binet Stage A Patients: Analysis of Immunodeficiency, Autoimmune Constellations and Infections in the CLL1-Protocol.
Kwag, Doo Young
core +1 more source
Role of ofatumumab in treatment of chronic lymphocytic leukemia [PDF]
Marays Veliz, Javier Pinilla-IbarzH Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USAAbstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal ...
Pinilla-Ibarz J +3 more
core +1 more source

